Ernexa Therapeutics Advances ERNA-101 Toward Phase 1 Trial
Cambridge, Massachusetts, August 10, 2026 Ernexa Therapeutics announced the appointment of David Polinsky to its Board of Directors as...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Cambridge, Massachusetts, August 10, 2026 Ernexa Therapeutics announced the appointment of David Polinsky to its Board of Directors as...
Vancouver, British Columbia, August 11, 2026 Genome BC has announced six research projects supported through its Data Access, Integration...
